---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071387"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:58:51.674856+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M

## Summary
- Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.
- Cash, equivalents and marketable securities $289.6M; runway into late 2027.
- ELVN-001 Phase 1 ENABLE: 44% (16/36) cumulative MMR by 24 weeks, well-tolerated, 74 patients.
- Strategic alternatives for ELVN-002 program; not pursued beyond 2025 to extend cash runway.
- Updated ELVN-001 data to be presented at EHA Congress in June; webcast June 13.

## SEC filing metadata
- accession: 0000950170-25-071387
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/0000950170-25-071387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/elvn-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071387
- JSON: https://secwatch.observer/filing/0000950170-25-071387.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.